These findings are in accordance with recent data from Imamura et al. [13], where higher expression of VEGF and increased MVD were observed in GIST tumors harboring a KIT mutation associated with resistance to imatinib. This evidence concerns the gene VEGFA and gastrointestinal stromal tumor.